These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 39167797)

  • 21. Chemoradiation triggers antitumor Th1 and tissue resident memory-polarized immune responses to improve immune checkpoint inhibitors therapy.
    Lauret Marie Joseph E; Kirilovsky A; Lecoester B; El Sissy C; Boullerot L; Rangan L; Marguier A; Tochet F; Dosset M; Boustani J; Ravel P; Boidot R; Spehner L; Haicheur-Adjouri N; Marliot F; Pallandre JR; Bonnefoy F; Scripcariu V; Van den Eynde M; Cornillot E; Mirjolet C; Pages F; Adotevi O
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34230108
    [TBL] [Abstract][Full Text] [Related]  

  • 22. T cell-mediated targeted delivery of tadalafil regulates immunosuppression and polyamine metabolism to overcome immune checkpoint blockade resistance in hepatocellular carcinoma.
    Wang X; Zhang Q; Zhou J; Xiao Z; Liu J; Deng S; Hong X; Huang W; Cai M; Guo Y; Huang J; Wang Y; Lin L; Zhu K
    J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36813307
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of a machine learning-based radiomics signature for estimating breast cancer TME phenotypes and predicting anti-PD-1/PD-L1 immunotherapy response.
    Han X; Guo Y; Ye H; Chen Z; Hu Q; Wei X; Liu Z; Liang C
    Breast Cancer Res; 2024 Jan; 26(1):18. PubMed ID: 38287356
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Impact of NOTCH Pathway Alteration on Tumor Microenvironment and Clinical Survival of Immune Checkpoint Inhibitors in NSCLC.
    Li X; Wang Y; Li X; Feng G; Hu S; Bai Y
    Front Immunol; 2021; 12():638763. PubMed ID: 34305884
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PI3Kγδ inhibitor plus radiation enhances the antitumour immune effect of PD-1 blockade in syngenic murine breast cancer and humanised patient-derived xenograft model.
    Han MG; Jang BS; Kang MH; Na D; Kim IA
    Eur J Cancer; 2021 Nov; 157():450-463. PubMed ID: 34601286
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Challenges and opportunities for cancer stem cell-targeted immunotherapies include immune checkpoint inhibitor, cancer stem cell-dendritic cell vaccine, chimeric antigen receptor immune cells, and modified exosomes.
    Alqarni A; Jasim SA; Altalbawy FMA; Kaur H; Kaur I; Rodriguez-Benites C; Deorari M; Alwaily ER; Al-Ani AM; Redhee AH
    J Biochem Mol Toxicol; 2024 Jun; 38(6):e23719. PubMed ID: 38764138
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immuno-Metabolism: The Role of Cancer Niche in Immune Checkpoint Inhibitor Resistance.
    Weng CY; Kao CX; Chang TS; Huang YH
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33514004
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mechanisms of primary and acquired resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer: A multiplex immunohistochemistry-based single-cell analysis.
    Isomoto K; Haratani K; Tsujikawa T; Makutani Y; Kawakami H; Takeda M; Yonesaka K; Tanaka K; Iwasa T; Hayashi H; Ito A; Nishio K; Nakagawa K
    Lung Cancer; 2022 Dec; 174():71-82. PubMed ID: 36347190
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regulation of autophagy fires up the cold tumor microenvironment to improve cancer immunotherapy.
    Jin Z; Sun X; Wang Y; Zhou C; Yang H; Zhou S
    Front Immunol; 2022; 13():1018903. PubMed ID: 36300110
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tissue biomarkers of immune checkpoint inhibitor therapy.
    Davoudi F; Moradi A; Sadeghirad H; Kulasinghe A
    Immunol Cell Biol; 2024 Mar; 102(3):179-193. PubMed ID: 38228572
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Construction of Hierarchically Biomimetic Iron Oxide Nanosystems for Macrophage Repolarization-Promoted Immune Checkpoint Blockade of Cancer Immunotherapy.
    Kang Y; Yan J; Han X; Wang X; Wang Y; Song P; Su X; Rauf A; Jin X; Pu F; Zhang H
    ACS Appl Mater Interfaces; 2024 Jul; 16(28):36131-36141. PubMed ID: 38979627
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumour microenvironment (TME) characterization identified prognosis and immunotherapy response in muscle-invasive bladder cancer (MIBC).
    Cao R; Yuan L; Ma B; Wang G; Tian Y
    Cancer Immunol Immunother; 2021 Jan; 70(1):1-18. PubMed ID: 32617668
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune-related gene-based prognostic index for predicting survival and immunotherapy outcomes in colorectal carcinoma.
    Liang Z; Sun R; Tu P; Liang Y; Liang L; Liu F; Bian Y; Yin G; Zhao F; Jiang M; Gu J; Tang D
    Front Immunol; 2022; 13():944286. PubMed ID: 36591255
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CC-01 (chidamide plus celecoxib) modifies the tumor immune microenvironment and reduces tumor progression combined with immune checkpoint inhibitor.
    Chen JS; Chou CH; Wu YH; Yang MH; Chu SH; Chao YS; Chen CN
    Sci Rep; 2022 Jan; 12(1):1100. PubMed ID: 35058524
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modulating tumor-associated macrophages to enhance the efficacy of immune checkpoint inhibitors: A TAM-pting approach.
    Chamseddine AN; Assi T; Mir O; Chouaib S
    Pharmacol Ther; 2022 Mar; 231():107986. PubMed ID: 34481812
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Computational construction of TME-related lncRNAs signature for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma.
    Zhou L; Fang H; Guo F; Yin M; Long H; Weng G
    J Clin Lab Anal; 2022 Aug; 36(8):e24582. PubMed ID: 35808868
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer.
    Jiang J; Jin Z; Zhang Y; Peng L; Zhang Y; Zhu Z; Wang Y; Tong D; Yang Y; Wang J; Yang Y; Xiao K
    Front Immunol; 2021; 12():646874. PubMed ID: 33927719
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prediction of survival and immunotherapy response by the combined classifier of G protein-coupled receptors and tumor microenvironment in melanoma.
    Shen K; Wang Q; Wang L; Yang Y; Ren M; Li Y; Gao Z; Zheng S; Ding Y; Ji J; Wei C; Zhang T; Zhu Y; Feng J; Qin F; Yang Y; Wei C; Gu J
    Eur J Med Res; 2023 Sep; 28(1):352. PubMed ID: 37716991
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genes associated with cellular senescence favor melanoma prognosis by stimulating immune responses in tumor microenvironment.
    Liang X; Lin X; Lin Z; Lin W; Peng Z; Wei S
    Comput Biol Med; 2023 May; 158():106850. PubMed ID: 37031510
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biomarkers and computational models for predicting efficacy to tumor ICI immunotherapy.
    Qin Y; Huo M; Liu X; Li SC
    Front Immunol; 2024; 15():1368749. PubMed ID: 38524135
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.